Agios Pharmaceutical (AGIO) 36.74 $AGIO How These

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2016 at 3:04 AM

Agios Pharmaceutical (AGIO) 36.74 $AGIO

How These Biotech Stocks are Faring? -- Progenics Pharma, Peregrine Pharma, Agios Pharma, and Cara Therapeutics
PR Newswire - Fri Aug 26, 6:50AM CDT
Stock-Callers.com has initiated research reports on the following Biotech companies: Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), and Cara Therapeutics Inc. (NASDAQ: CARA). On Wednesday, August 24, 2016, the iShares NASDAQ Biotechnology ETF (IBB) plummeted 3% after Democratic presidential candidate Hillary Clinton tweeted about the price hikes on EpiPens. Register now and get full and free access to our downloadable research reports on these stocks at:
CARA: 5.38 (-0.04), PGNX: 6.14 (-0.14), PPHM: 0.36 (unch), AGIO: 36.74 (-0.10)

Agios Appoints Andrew Hirsch as Chief Financial Officer
GlobeNewswire - Tue Aug 16, 6:30AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that Andrew Hirsch is joining the company as chief financial officer, effective September 19, 2016. Mr. Hirsch has more than 20 years of experience in a range of strategic and operating roles in the biotechnology sector, most recently having served as president and chief executive officer of BIND Therapeutics.
AGIO: 36.74 (-0.10), BIND: 0.78 (-0.09)

Agios (AGIO) Q2 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 10:10AM CDT
Agios Pharmaceuticals (AGIO) reported a wider-than-expected second-quarter 2016 loss of $1.47 per share.
GERN: 2.73 (+0.04), AGIO: 36.74 (-0.10), ANIK: 47.94 (+0.70), CELG: 106.37 (-0.37)

Agios to Present at Canaccord Genuity 36th Annual Growth Conference Wednesday, August 10, 2016
GlobeNewswire - Fri Aug 05, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present at the Canaccord Genuity 36th Annual Growth Conference in Boston on Wednesday, August 10, 2016 at 8:00 a.m. ET.
AGIO: 36.74 (-0.10)

Agios (AGIO) Reports Wider-than-Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:50AM CDT
Agios (AGIO) posted wider-than-expected loss in the second quarter of 2016.
AGIO: 36.74 (-0.10)

Agios Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 6:01AM CDT
- Data from PKR Activators at EHA Demonstrated Proof-of-Concept for AG-348 and Proof-of-Mechanism for AG-519; Program Moving Toward Pivotal Development in PK Deficiency with Molecule Selection by Year-End 2016 -
AGIO: 36.74 (-0.10)

Medical Product Stock Earnings on Aug 4: NXTM, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:56AM CDT
Here, we take a look at four Medical product stocks set to report their quarterly figures on Aug 4.
NXTM: 22.86 (unch), AGIO: 36.74 (-0.10), ATRC: 15.50 (+0.11), HRC: 59.25 (-0.06)

Will Agios (AGIO) Disappoint Estimates in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 10:23AM CDT
Agios Pharmaceuticals (AGIO), which is set to report second-quarter 2016 results on Aug 4, had posted a positive surprise of 11.59% last quarter.
ICPT: 146.82 (-1.49), AGIO: 36.74 (-0.10), EXEL: 11.35 (+0.20), CELG: 106.37 (-0.37)

Agios to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016
GlobeNewswire - Thu Jul 28, 3:01PM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2016 at 8:30 a.m. ET to report its second quarter 2016 financial results and discuss recent clinical development and corporate activities.
AGIO: 36.74 (-0.10)

Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 34.68 (-0.12), RTRX: 16.35 (+0.33), AGIO: 36.74 (-0.10), BMY: 56.76 (-0.63)

Agios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers
GlobeNewswire - Thu Jun 09, 8:21AM CDT
- Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing -
AGIO: 36.74 (-0.10)

What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.45 (+0.01), INSY: 14.36 (+0.09), AGIO: 36.74 (-0.10), GNCA: 5.28 (-0.08)

Agios to Host Conference Call from the 21st Congress of the European Hematology Association
GlobeNewswire - Wed Jun 01, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Saturday, June 11, 2016 at 9:30 a.m. ET to discuss clinical and preclinical data presented at the 21st Congress of the European Hematology Association (EHA) taking place June 9-12, 2016 in Copenhagen.
AGIO: 36.74 (-0.10)

Agios to Present Clinical and Preclinical Data from PKR Activators AG-348 and AG-519 at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 6:01AM CDT
Initial Data to be Presented from AG-348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study
AGIO: 36.74 (-0.10)

Agios Strikes Metabolic Immuno-Oncology Deal with Celgene
Zacks Equity Research - Zacks Investment Research - Wed May 18, 10:00AM CDT
Agios Pharmaceuticals (AGIO) inked a metabolic immuno-oncology agreement with Celgene; Agios gained global rights to AG-120 and updated 2016 view.
ANIP: 61.42 (+1.68), RTRX: 16.35 (+0.33), AGIO: 36.74 (-0.10), CELG: 106.37 (-0.37)

Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement
GlobeNewswire - Tue May 17, 3:01PM CDT
- New Collaboration Builds on Agios Research Platform and Leverages Celgene Capabilities; Agios to Receive $200 Million Upfront Payment -
AGIO: 36.74 (-0.10), CELG: 106.37 (-0.37), CELGZ: 1.13 (-0.03)

Agios (AGIO) Q1 Loss Lower than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:51AM CDT
Agios Pharmaceuticals (AGIO) reported a first-quarter 2016 loss of 61 cents per share, much narrower than the Zacks Consensus Estimate of a loss of 69 cents.
ANIP: 61.42 (+1.68), RTRX: 16.35 (+0.33), AGIO: 36.74 (-0.10), CELG: 106.37 (-0.37)

Agios Pharmaceuticals reports 1Q loss
Automated Insights - Thu May 05, 2:45PM CDT
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Thursday reported a loss of $23.2 million in its first quarter.
AGIO: 36.74 (-0.10)

Agios Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 6:01AM CDT
Five Abstracts Accepted for Presentation at EHA in June, Including First Data from AG -348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study
AGIO: 36.74 (-0.10)

Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 42.30 (+0.28), BIIB: 306.03 (+0.40), CNAT: 1.86 (+0.05), AMGN: 170.13 (+0.07), RPRX: 2.00 (-0.03), JNJ: 119.08 (-0.26), GILD: 77.42 (-0.96), GWPH: 82.28 (+0.53), GERN: 2.73 (+0.04), AVEO: 0.91 (-0.02), ICPT: 146.82 (-1.49), AGIO: 36.74 (-0.10), NVS: 78.27 (-0.50)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Calavera NY Website Revamp: Gemstone Expansion Hits

Calavera New York's Bold Online Makeover When a jewelry brand that's all about slashing retail markups makes a move this big, it's worth a real close-up look. Calavera New York, a name buzzing in the diamond and gemstone scene, just dropped a redesigned website that’s turning more than a few heads. They’re known for cutting out the middleman, a strategy that already...

IRS Views Challenge Tax-Engineered Healthcare Schemes

Nonprofit Models Shine Amid IRS Scrutiny Out in Oxnard, California, there's a brewing storm in the healthcare sector. No, it's not a billing error or yet another scandal. We're talking about a seismic shift that could poke holes in those tax-engineered Section 105(b) programs, all thanks to some hard-hitting IRS memoranda. The Nonprofit–TPA Model: A Safer Bet? Enter...

Menopause Policy Advocacy Takes Center Stage in DC

Unlikely Spotlight on Menopause at Capitol Hill If you told me a couple of years back that menopause would become a front-page political issue, I would've laughed. Yet, here we are, with over 125 advocates from 29 states converging on Washington, D.C., demanding legislative action on menopause. Why Menopause Matters in Policy The fact that more than half the population is...

Bellissima Bags Allure Award for Curly Hair Tool

Award-Winning Tool Headlines 2026 Beauty Scene There's a shake-up in the world of hair tools, folks. Bellissima's Diffon Supreme has snagged a 2026 Allure Best of Beauty Award for its prowess in taming the curly, wavy, and coily strands we all crave to manage. Performance Meets Innovation in Bellissima's Latest Let's not beat around the bush. The Diffon Supreme's trump...

Ensuring Your Radon Mitigation System Stays Effective

Radon Mitigation: A Critical Measure for Home Safety Homeowners, you're probably aware of the ticking health time bomb known as radon. Not just an annoying gas, this colorless, odorless beast lurks quietly, threatening family health if not managed right. Mitch Kelley, a specialist in radon testing with Basement Solutions in Mankato, Minnesota, lays out a no-fuss guide to...

Buffett Steps Down, New Faces at Berkshire Hathaway

End of an Era: Warren Buffett's Retirement Warren Buffett—there's a name that's echoed through the halls of investment for decades. Today, he's pulling down the curtain as Chairman of Berkshire Hathaway (NYSE: BRK). No fanfare, just a nod to the inevitable with his classic, humor-tinged confession: 'Father Time always wins.' Can’t argue with the man who’s seen the...

AI Ambassadors Rethink Arbitration's Future

Navigating the AI Terrain in Arbitration It's 2026 and artificial intelligence isn't just a buzzword anymore; it's reshaping every corner of how disputes get resolved. The American Arbitration Association (AAA) has jumped into the mix, launching an AI Ambassador program to tackle a wave of AI-induced challenges. These aren't just academic exercises—this is a hard-nosed...

Sierra Ridge Advisors Join Gateway Financial Milestone

Big Moves in the Financial Advisory World Let's dive right in. Here's a real shakeup in the advisory realm: 28 financial advisors and team members from Sierra Ridge Advisor Group are packing their bags for Gateway Financial Partners. We're talking about a significant shift involving $825 million in assets under advisement. Instead of sticking with Sierra Ridge as it...

Kobold Press Explores Roleplaying as Literacy Tool

Gaming Illuminates Pathways to Literacy and Community Trust me, when an indie game publisher like Kobold Press makes waves, it's worth paying attention. They've carved a niche in the roleplaying world by marrying traditional game elements with valuable educational tools. The thrill of the game goes beyond rolling dice; it's a ticket to improving literacy, arithmetic, and...

Arizona Voters Demand Clear Plans for 2026 Election

A Shift in Voter Expectations: Clear Actions Needed Arizona voters have spoken, and they aren't looking for the same old political song and dance anymore. They crave something meatier—action, not just words. Heading into the 2026 general election, folks in the Grand Canyon State are demanding concrete solutions and straightforward answers from those who seek to lead...